{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:26:22Z","timestamp":1790504782254,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"European Research Council","award":["681219"],"award-info":[{"award-number":["681219"]}]},{"name":"Helsinki Institute of Life Science"},{"DOI":"10.13039\/501100004012","name":"Jane and Aatos Erkko Foundation","doi-asserted-by":"crossref","award":["170046"],"award-info":[{"award-number":["170046"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ymthe.2018.06.008","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T21:53:10Z","timestamp":1529445190000},"page":"2315-2325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses"],"prefix":"10.1016","volume":"26","author":[{"given":"Erkko","family":"Yl\u00f6sm\u00e4ki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Malorzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oona","family":"Honkasalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlio","family":"Fusciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Yl\u00f6sm\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Louna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Feola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Paavilainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karita","family":"Peltonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veijo","family":"Hukkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapani","family":"Viitala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2018.06.008_bib1","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","article-title":"Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma","volume":"77","author":"Clemente","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2018.06.008_bib2","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2018.06.008_bib3","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.06.008_bib4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/onc.2009.416","article-title":"Immune infiltration in human tumors: a prognostic factor that should not be ignored","volume":"29","author":"Pag\u00e8s","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2018.06.008_bib5","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T\u00a0cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.06.008_bib6","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"Ott","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.06.008_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ymthe.2018.06.008_bib8","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.24951","article-title":"Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival","volume":"116","author":"Ku","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2018.06.008_bib9","doi-asserted-by":"crossref","first-page":"16723","DOI":"10.1073\/pnas.1110814108","article-title":"Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical","volume":"108","author":"Yuan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.06.008_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ebiom.2016.06.046","article-title":"Oncolytic Viruses: Therapeutics With an Identity Crisis","volume":"9","author":"Breitbach","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2018.06.008_bib11","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.170.10.4905","article-title":"Induction of tumor cell apoptosis in\u00a0vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T\u00a0cells","volume":"170","author":"Nowak","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.06.008_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.cdd.4402255","article-title":"Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all","volume":"15","author":"van der Most","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ymthe.2018.06.008_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2018.06.008_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2018.06.008_bib15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0065-3233(03)01010-6","article-title":"Enveloped viruses","volume":"64","author":"Kuhn","year":"2003","journal-title":"Adv. Protein Chem."},{"key":"10.1016\/j.ymthe.2018.06.008_bib16","doi-asserted-by":"crossref","first-page":"e1105429","DOI":"10.1080\/2162402X.2015.1105429","article-title":"Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma","volume":"5","author":"Capasso","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2018.06.008_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0092-8674(88)91043-4","article-title":"Introduction of soluble protein into the class I pathway of antigen processing and presentation","volume":"54","author":"Moore","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.06.008_bib18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1006\/mthe.2000.0240","article-title":"Development of a syngenic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1","volume":"3","author":"Miller","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.06.008_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ilar\/ilw002","article-title":"Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses","volume":"57","author":"Speranza","year":"2016","journal-title":"ILAR J."},{"key":"10.1016\/j.ymthe.2018.06.008_bib20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4049\/jimmunol.1201209","article-title":"Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge","volume":"190","author":"Baird","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.06.008_bib21","doi-asserted-by":"crossref","first-page":"e0115827","DOI":"10.1371\/journal.pone.0115827","article-title":"Local immunosuppressive microenvironment enhances migration of melanoma cells to lungs in DJ-1 knockout mice","volume":"10","author":"Chien","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2018.06.008_bib22","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.4049\/jimmunol.161.10.5516","article-title":"Eliciting T\u00a0cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines","volume":"161","author":"Wang","year":"1998","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.06.008_bib23","doi-asserted-by":"crossref","first-page":"e87831","DOI":"10.1371\/journal.pone.0087831","article-title":"Quantification of B16 melanoma cells in lungs using triplex Q-PCR\u2014a new approach to evaluate melanoma cell metastasis and tumor control","volume":"9","author":"Sorensen","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2018.06.008_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00262-011-1164-6","article-title":"Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation","volume":"61","author":"Umansky","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2018.06.008_bib25","doi-asserted-by":"crossref","first-page":"e88328","DOI":"10.1172\/jci.insight.88328","article-title":"Lack of immunoediting in murine pancreatic cancer reversed with neoantigen","volume":"1","author":"Evans","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2018.06.008_bib26","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.celrep.2016.10.086","article-title":"Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8\u00a0T Cell Responses","volume":"17","author":"Knocke","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.ymthe.2018.06.008_bib27","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ymthe.2018.06.008_bib28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2018.06.008_bib29","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.06.008_bib30","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.06.008_bib31","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.06.008_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1457596","article-title":"Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors","author":"Feola","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2018.06.008_bib33","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1038\/mto.2016.2","article-title":"Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity","volume":"3","author":"Hirvinen","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2018.06.008_bib34","doi-asserted-by":"crossref","first-page":"e64200","DOI":"10.1371\/journal.pone.0064200","article-title":"A herpes simplex virus-derived replicative vector expressing LIF limits experimental demyelinating disease and modulates autoimmunity","volume":"8","author":"Nyg\u00e5rdas","year":"2013","journal-title":"PLoS ONE"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618302673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618302673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T07:39:58Z","timestamp":1693726798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001618302673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1525001618302673"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.06.008","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors.","name":"copyright","label":"Copyright"}]}}